| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 130- | CUR, | Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 14- | CUR, | Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway |
| - | vitro+vivo, | Pca, | PC3 |
| 12- | CUR, | Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells |
| - | in-vitro, | MB, | DAOY |
| 167- | CUR, | Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria |
| - | in-vitro, | Pca, | PC3 |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| 3579- | CUR, | AgNPs, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | NA, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 4830- | CUR, | Curcumin and Its Derivatives Induce Apoptosis in Human Cancer Cells by Mobilizing and Redox Cycling Genomic Copper Ions |
| - | in-vitro, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2812- | CUR, | Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 2808- | CUR, | Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation |
| - | in-vitro, | Liver, | HUH7 |
| 2978- | CUR, | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 6238- | CUSP9, | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| - | Trial, | GBM, | NA |
| 6236- | CUSP9, | EP, | Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro |
| - | in-vitro, | GBM, | U251 |
| 6239- | CUSP9, | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy |
| - | in-vitro, | GBM, | NA |
| 6241- | CUSP9, | RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 |
| - | Trial, | GBM, | NA |
| 6245- | Cyc, | Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers |
| - | vitro+vivo, | PC, | NA |
| 6252- | Cyc, | Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance |
| - | Review, | Var, | NA |
| 7449- | CYN, | Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines |
| - | in-vitro, | lymphoma, | U937 | - | in-vitro, | AML, | Jurkat |
| 7444- | CYN, | The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress |
| - | in-vitro, | GBM, | U87MG |
| 7442- | CYN, | Cynaropicrin induces the apoptosis of colorectal cancer cells by elevating reactive oxygen species and activating the JNK/p38 MAPK |
| - | in-vitro, | CRC, | HCT116 |
| 7439- | CYN, | Cynaropicrin Induces Reactive Oxygen Species-Dependent Paraptosis-Like Cell Death in Human Liver Cancer Cells |
| - | in-vitro, | Liver, | Hep3B |
| 7438- | CYN, | Cynaropicrin Suppresses Cell Proliferation by Inducing Mitophagy through p38 MAPK-Mediated Mitochondrial ROS Generation in Human Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | NA |
| 6264- | Cyste, | Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine |
| - | Review, | Nor, | NA |
| 6262- | Cyste, | A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety |
| - | Trial, | Nor, | NA |
| 6261- | Cyste, | A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 6684- | DAP, | GB, | Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells |
| - | vitro+vivo, | NSCLC, | H1975 |
| 6593- | DAS, | Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors |
| 6591- | DAS, | Dasatinib in solid tumors |
| - | Review, | Var, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6682- | DCA, | QC, | Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer |
| - | in-vivo, | HNSCC, | MEER |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| 6679- | DCA, | GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial |
| - | Trial, | Melanoma, | NA |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1876- | DCA, | Chemo, | In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines |
| - | in-vivo, | Lung, | H727 |
| 1875- | DCA, | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
| - | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1881- | DCA, | Chemo, | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report |
| - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | WI38 | - | Case Report, | Var, | NA |
| 1884- | DCA, | Sal, | Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1870- | DCA, | Rad, | Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation |
| - | in-vitro, | Pca, | PC3 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 1867- | DCA, | Chemo, | Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | NA |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid